Search results for "Orbital radiotherapy"
showing 2 items of 2 documents
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy
2015
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mech anisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations …
Radiotherapy for Graves’ ophthalmopathy
2000
The interest in the treatment of benign diseases with radiation therapy has grown particularly in the Western part of the world. In 1996, a questionnaire was sent to 1348 institutes worldwide listed in the directory of the Society for Therapeutic Radiology and Oncology asking whether the respondents considered a list of 28 most common benign disorders as being a good indication for orbital radiotherapy.1 Questions concerned the frequency of such treatments and the treatment schedules used. The prevention of keloid formation was the most widely accepted indication, followed by Graves’ ophthalmopathy. Thus, radiotherapy for this orbital disorder is generally accepted and applied worldwide.